COVID-19 and inequities in colorectal and cervical cancer screening and diagnosis in Washington State.
COVID-19
cervical cancer
colorectal cancer
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
revised:
14
12
2021
received:
28
10
2021
accepted:
17
12
2021
pubmed:
20
3
2022
medline:
11
8
2022
entrez:
19
3
2022
Statut:
ppublish
Résumé
Studies have shown that cancer screenings dropped dramatically following the onset of the coronavirus diseases 2019 (COVID-19) pandemic. In this study, we examined differences in rates of cervical and colorectal cancer (CRC) screening and diagnosis indicators before and during the first year of the COVID-19 pandemic. We used retrospective data from a large healthcare system in Washington State. Targeted screening data included completed cancer screenings for both CRC (colonoscopy) and cervical cancer (Papanicolaou test (Pap test)). We analyzed and compared the rate of uptake of colorectal (colonoscopies) and cervical cancer (Pap) screenings done pre-COVID-19 (April 1, 2019-March 31, 2020) and during the pandemic (April 1, 2020-March 31, 2021). A total of 26,081 (12.7%) patients underwent colonoscopies in the pre-COVID-19 period, compared to only 15,708 (7.4%) patients during the pandemic, showing a 39.8% decrease. A total of 238 patients were referred to medical oncology for CRC compared to only 155 patients during the first year of the pandemic, a reduction of 34%. In the pre-COVID-19 period, 22,395 (10.7%) women were administered PAP tests compared to 20,455 (9.6%) women during the pandemic, for a 7.4% reduction. period 1780 women were referred to colposcopy, compared to only 1680 patients during the pandemic, for a 4.3% reduction. Interruption in screening and subsequent delay in diagnosis during the pandemic will likely lead to later-stage diagnoses for both CRC and cervical cancer, which is known to result in decreased survival. The results emphasize the need to prioritize cancer screening, particularly for those at higher risk.
Identifiants
pubmed: 35304835
doi: 10.1002/cam4.4655
pmc: PMC9110900
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2990-2998Informations de copyright
© 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Health Serv Res. 2021 Feb;56(1):95-101
pubmed: 33146429
JAMA Netw Open. 2021 May 3;4(5):e2110946
pubmed: 34028552
BMC Health Serv Res. 2008 Dec 01;8:245
pubmed: 19046443
Arch Intern Med. 2007 Feb 12;167(3):258-64
pubmed: 17296881
Am J Gastroenterol. 2015 Oct;110(10):1388-94
pubmed: 25964227
J Natl Cancer Inst. 2021 Aug 2;113(8):962-968
pubmed: 32780851
Cancer Epidemiol Biomarkers Prev. 2009 Jan;18(1):121-31
pubmed: 19124489
Lancet Oncol. 2020 Aug;21(8):1023-1034
pubmed: 32702310
Clin Colorectal Cancer. 2021 Mar;20(1):e5-e11
pubmed: 32868231
Semin Oncol Nurs. 2017 May;33(2):172-183
pubmed: 28343836
Lancet Gastroenterol Hepatol. 2020 Aug;5(8):726-727
pubmed: 32569576
Cancer Med. 2022 Aug;11(15):2990-2998
pubmed: 35304835
Prev Med. 2021 Oct;151:106596
pubmed: 34217415
Semin Oncol Nurs. 2017 May;33(2):121-128
pubmed: 28343835
Prev Med. 2021 Oct;151:106559
pubmed: 34217410
JAMA Oncol. 2021 Mar 1;7(3):458-460
pubmed: 33443549
Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):1968-73
pubmed: 18708386
Front Public Health. 2015 Apr 15;3:51
pubmed: 25932459
Gastroenterology. 2012 Jun;142(7):1460-7.e2
pubmed: 22446606
Gastrointest Endosc. 2020 Oct;92(4):946-950
pubmed: 32574570